Radiolabeled meta-iodobenzylguanidine: pharmacology and clinical studies.
Much was known of the pharmacology of meta-iodobenzylguanidine (MIBG) before its clinical use, but we have since learned a good deal more about the metabolic distribution and fate of this radiopharmaceutical. And, as is the nature of science, more is yet to be discovered. This communication reviews what is known about the pharmacology of radiolabeled MIBG and how this pharmacology affects the clinical studies that use the agent.
Sisson
J C
JC
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109.
Wieland
D M
DM
D019797:3-Iodobenzylguanidine; D000310:Adrenal Gland Neoplasms / Q000000981:diagnostic imaging; D000818:Animals; D006801:Humans; D007457:Iodine Radioisotopes; D007462:Iodobenzenes / Q000378:metabolism / Q000493:pharmacokinetics; D010673:Pheochromocytoma / Q000000981:diagnostic imaging; D011877:Radionuclide Imaging
D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D019797:3-Iodobenzylguanidine